The biotech has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its spinocerebellar ...

Shares of US clinical-stage biotech Biohaven (NYSE: BHVN) rose 9.6% to $21.74 yesterday, after it announced an agreement with ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

Since 2020, Pfizer has made significant investments in acquisitions, including Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics (GBT) for $5.4 billion ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...

Pfizer Inc. PFE) on Tuesday reported first-quarter profit of $2.97 billion. On a per-share basis, the New York-based company said it had profit of 52 cents.

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...